TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7762909

Group type: EXPERIMENTAL
Intervention: Ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered
Number of subjects: 113

Group type: COMPARATOR
Intervention: No anticytomegalovirus therapy
Number of subjects: 113
Study: 2306420

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg HCl for 4 days
Number of subjects: 10
Study: 7423172

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 30590600

Group type: EXPERIMENTAL
Intervention: Uninterrupted (UI) non-vitamin K antagonist oral anticoagulants (NOACs)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Single-dose skipped (SDS) NOACs
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 24-hour skipped (24S) NOACs
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: All groups (UI, SDS, 24S)
Number of subjects: 326
Study: 28702717

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Video online support group
Number of subjects: 46
Study: 25754330

Group type: COMPARATOR
Intervention: Tildrakizumab 3 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tildrakizumab 10 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Tildrakizumab 3 mg/kg and 10 mg/kg (pooled)
Number of subjects: 29
Study: 22848074

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (200 µg via ipsilateral peripheral vein about 3 min before puncture)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no nitroglycerin)
Number of subjects: 40
Study: 21878237

Group type: EXPERIMENTAL
Intervention: Prehabilitation program (stationary cycling plus weight training)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Prehabilitation program (recommendation to increase walking and breathing exercises)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Prehabilitation (general)
Number of subjects: 95
Study: 19167925

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg daily
Number of subjects: 3098

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3098
Study: 17391951

Group type: EXPERIMENTAL
Intervention: IFN‐gamma‐1b (200 microg subcutaneously three times per week for 24 months)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Colchicine (1mg orally per day for 24 months)
Number of subjects: 14
Study: 14971971

Group type: EXPERIMENTAL
Intervention: Olympic lifting (OL) group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Power lifting (PL) group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both OL and PL groups
Number of subjects: 20
Study: 11249725

Group type: EXPERIMENTAL
Intervention: BLP-25 vaccine with IL-2 in a liposomal delivery system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 9218922

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 167

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 167
Study: 7957536

Group type: EXPERIMENTAL
Intervention: Hexarelin 0.5 micrograms.kg‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexarelin 1 microgram.kg‐1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hexarelin 2 micrograms.kg‐1
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3481508

Group type: EXPERIMENTAL
Intervention: Intra-amniotic PGF2 alpha 40 mg followed by oxytocin stimulation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 1.0 mg in gel for 4 h followed by intra-amniotic PGF2 alpha 40 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intracervical PGE2 1.0 mg in gel
Number of subjects: 28
Study: 30142427

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (regular exercise)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 154
Study: 26850877

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) dexmedetomidine (1.0 μg/kg)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) dexmedetomidine (1.5 μg/kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Local anesthesia
Number of subjects: 240
Study: 25511923

Group type: EXPERIMENTAL
Intervention: Gemcitabine maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erlotinib maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 23377520

Group type: EXPERIMENTAL
Intervention: ALA with occlusion (ALA+OCC)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nonoccluded ALA
Number of subjects: 70

Group type: COMPARATOR
Intervention: VEH with occlusion (VEH+OCC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nonoccluded VEH
Number of subjects: 70
Study: 20375028

Group type: EXPERIMENTAL
Intervention: Community care (n = 33)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (n = 32)
Number of subjects: 65
Study: 18184543

Group type: EXPERIMENTAL
Intervention: Western medicine (WM) therapy including voltaren extended action tablet, methotrexate, and sulfasalazine
Number of subjects: 413

Group type: COMPARATOR
Intervention: Traditional Chinese medicine (CM) therapy including glucosidorum Tripterygll totorum tablet and Yishen Juanbi Tablet
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Western medicine (WM) therapy
Number of subjects: 413
Study: 15250433

Group type: EXPERIMENTAL
Intervention: Venlafaxine (maximum tolerated dose, 75 mg in most cases)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 30
Study: 12566887

Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide instilled in treated eyes after PRK
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated eyes (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide in treated eyes with myopia above 6 diopters
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated eyes with myopia above 6 diopters (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 0.1% tropicamide in treated eyes with cornea thinner than 540 micrometers
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated eyes with cornea thinner than 540 micrometers (control)
Number of subjects: 28
Study: 9717594

Group type: EXPERIMENTAL
Intervention: 5 IU oxytocin i.v. and 2 ml saline imy
Number of subjects: 40

Group type: COMPARATOR
Intervention: 20 IU oxytocin into the myometrium and 0.5 ml saline i.v.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (i.v. and imy oxytocin)
Number of subjects: 40
Study: 8628581

Group type: EXPERIMENTAL
Intervention: Ketamine (mean dose: 32 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alfentanil (mean dose: 3075 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 12
Study: 2501394

Group type: EXPERIMENTAL
Intervention: Mupirocin (Bactroban) ointment applied twice daily for 7 days
Number of subjects: 413

Group type: COMPARATOR
Intervention: Sodium fusidate (Fucidin) ointment applied thrice daily for 7 days
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 413

Group type: COMPARATOR
Intervention: Sodium fusidate
Number of subjects: 413
Study: 353089

Group type: EXPERIMENTAL
Intervention: 30 mg phenobarbital plus 8 mg belladonna (P & B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31676719

Group type: EXPERIMENTAL
Intervention: Home-based care from patient-nominated lay people trained to deliver intramuscular streptomycin.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Standard care (hospital-based management) for 2 months of streptomycin.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Home-based management.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Hospital-based management.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Home-based care and hospital-based care.
Number of subjects: 204
Study: 31436494

Group type: EXPERIMENTAL
Intervention: FBT+egg
Number of subjects: 50

Group type: COMPARATOR
Intervention: FBT+cereal
Number of subjects: 50
Study: 28835651

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 19
Study: 24706006

Group type: EXPERIMENTAL
Intervention: Methotrexate (initial treatment), followed by either sulfasalazine+hydroxychloroquine or infliximab for non-responders.
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Baseline erosions
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Erythrocyte sedimentation rate
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 311
Study: 23220209

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Number of subjects: 156

Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 156
Study: 21785396

Group type: EXPERIMENTAL
Intervention: Budesonide 0.25 mg/g cream in the morning and tacalcitol 4 µg/g ointment in the evening
Number of subjects: 20

Group type: COMPARATOR
Intervention: Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 mg/g ointment once daily
Number of subjects: 20
Study: 19346879

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam plus ceftazidime (PIPC/TAZ+CAZ)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Sulbactam/ampicillin plus aztreonam (SBT/ABPC+AZT)
Number of subjects: 134
Study: 16699359

Group type: EXPERIMENTAL
Intervention: Music therapy (20 minutes)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (20 minutes of quiet, uninterrupted rest)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Music therapy and Control
Number of subjects: 86
Study: 15567701

Group type: EXPERIMENTAL
Intervention: Heavy derivative PD control approach for insulin infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modelled insulin infused
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heavy derivative PD control approach
Number of subjects: 0
Study: 11699800

Group type: EXPERIMENTAL
Intervention: Adderall
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Immediate-release dextroamphetamine sulfate
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Spansules
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Immediate-release amphetamines
Number of subjects: 35
Study: 9085124

Group type: EXPERIMENTAL
Intervention: 100 micrograms of 105AD7
Number of subjects: 135

Group type: COMPARATOR
Intervention: 200 micrograms of 105AD7
Number of subjects: 135
Study: 7624642

Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiation therapy (20 and 45 Gy delivered in 10 and 15 fractions)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conventional fractionated radiation therapy
Number of subjects: 15
Study: 3688637

Group type: EXPERIMENTAL
Intervention: Indomethacin (Indocin SR 75 mg every 12 h for 5 days)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 14
Study: 28401441

Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent occupational rehabilitation (4+4 days) including Acceptance and Commitment Therapy (ACT), physical training, and work-related problem-solving.
Number of subjects: 168

Group type: COMPARATOR
Intervention: Outpatient rehabilitation (6 sessions during 6 weeks) primarily consisting of ACT.
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Inpatient multicomponent occupational rehabilitation (4+4 days).
Number of subjects: 168

Group type: COMPARATOR
Intervention: Outpatient rehabilitation (6 sessions during 6 weeks).
Number of subjects: 168
Study: 27927174

Group type: EXPERIMENTAL
Intervention: Complex mental health intervention for carers and case managers
Number of subjects: 176
Study: 24655702

Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard-of-care (SOC)
Number of subjects: 104
Study: 24138805

Group type: EXPERIMENTAL
Intervention: BBOFT+ intervention
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: E-health4Uth Healthy toddler intervention
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (care as usual)
Number of subjects: 51
Study: 20598577

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alphacalcidol
Number of subjects: 0
Study: 17940146

Group type: EXPERIMENTAL
Intervention: Open kinetic chain (OKC) quadriceps strengthening
Number of subjects: 42

Group type: COMPARATOR
Intervention: Closed kinetic chain (CKC) quadriceps strengthening
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups (CKC and OKC)
Number of subjects: 42
Study: 16521015

Group type: EXPERIMENTAL
Intervention: Custom-made radiolucent modular splint for stress radiographs
Number of subjects: 11

Group type: COMPARATOR
Intervention: Manual positioning for stress radiographs
Number of subjects: 11
Study: 12740743

Group type: EXPERIMENTAL
Intervention: Iron supplement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10826254

Group type: EXPERIMENTAL
Intervention: Short-term exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term exercise intervention
Number of subjects: 0
Study: 8775366

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (200 micrograms.d‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Resistive exercise training program (12 weeks, 3 times per week, 2 sets of 8-10 repetitions at 90% of 1 repetition maximum)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo group (no chromium supplementation)
Number of subjects: 16
Study: 1478163

Group type: EXPERIMENTAL
Intervention: Cefaclor 250 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Macrocrystalline nitrofurantoin 50 mg
Number of subjects: 80
Study: 3958952

Group type: EXPERIMENTAL
Intervention: Amvisc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 0
Study: 29217156

Group type: EXPERIMENTAL
Intervention: Air-Q®
Number of subjects: 33

Group type: COMPARATOR
Intervention: LMA Fastrach™
Number of subjects: 33
Study: 27210830

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral engagement intervention by phone
Number of subjects: 0
Study: 25182501

Group type: EXPERIMENTAL
Intervention: Neck coordination exercise
Number of subjects: 108

Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 108

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 108
Study: 22877506

Group type: EXPERIMENTAL
Intervention: Therapeutic platelet transfusion strategy (transfusion when bleeding occurred)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Prophylactic platelet transfusion strategy (transfusion when platelet counts were 10×10(9) per L or lower)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy in patients with acute myeloid leukaemia
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy in patients who had autologous transplantation
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Therapeutic strategy
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 391
Study: 20451898

Group type: EXPERIMENTAL
Intervention: Anisometropic amblyopia (with or without strabismus)
Number of subjects: 2635

Group type: EXPERIMENTAL
Intervention: Strabismic‐only amblyopia
Number of subjects: 2635
Study: 18271963

Group type: EXPERIMENTAL
Intervention: Influenza season defined by a three-week moving average of positive influenza isolates at least 5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza season defined by a three-week moving average of positive influenza isolates at least 10%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza season defined by first and last positive influenza isolate identified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Influenza season defined by 5% of total number of positive isolates for the season obtained
Number of subjects: 0
Study: 18416847

Group type: EXPERIMENTAL
Intervention: Extended sigh (eSigh)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 19
Study: 15143453

Group type: EXPERIMENTAL
Intervention: Interferon, ribavirin, and amantadin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 11748098

Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1003
Study: 8988938

Group type: EXPERIMENTAL
Intervention: Special intervention group with dietary goals of reduced saturated fat and cholesterol, and increased polyunsaturated fat; total fat intake decreased for energy control.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3-day food records scoring and subjective evaluation by nutritionists.
Number of subjects: 0
Study: 8214804

Group type: EXPERIMENTAL
Intervention: Large particle heated water vapor at 43 degrees C for 20 minutes (particle size 4 to 8 microns)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Molecular water vapor at 41 degrees C for 20 minutes (vapor phase)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal irrigation
Number of subjects: 30
Study: 3307717

Group type: EXPERIMENTAL
Intervention: Topical 1% ALO 2145 (p‐aminoclonidine hydrochloride)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31201057

Group type: EXPERIMENTAL
Intervention: Automated reminder to recommend the 2nd or 3rd dose of HPV vaccine
Number of subjects: 1285

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 1285
Study: 28454800

Group type: EXPERIMENTAL
Intervention: Intensive 37‐hour educational program for preschool children over 4 months
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Individual‐focused or peer‐to‐peer based intervention for adults
Number of subjects: 1200
Study: 26054139

Group type: EXPERIMENTAL
Intervention: Acupuncture group (abdominal acupuncture at specific points)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (basic treatment combined with oral administration of regular antidiabetics)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between acupuncture and medication groups
Number of subjects: 60
Study: 23537391

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 20820870

Group type: EXPERIMENTAL
Intervention: Type I tumors (25%) with EGFR amplification
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type II tumors (21.7%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type III tumors (11.7%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Type IV tumors (41.7%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Genomic type
Number of subjects: 60
Study: 19167667

Group type: EXPERIMENTAL
Intervention: Program X intervention (pedometers and e-mail support)
Number of subjects: 124
Study: 16704382

Group type: EXPERIMENTAL
Intervention: 4 live cases (n=32)
Number of subjects: 55

Group type: COMPARATOR
Intervention: 2 live and 2 virtual cases (n=23)
Number of subjects: 55
Study: 15546306

Group type: EXPERIMENTAL
Intervention: Active biventricular pacing (CRT)
Number of subjects: 110
Study: 11766094

Group type: EXPERIMENTAL
Intervention: Button‐bracket splint (BS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resin splint (RS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Titanium Trauma Splint (TTS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wire‐composite splint (WCS)
Number of subjects: 10
Study: 9246043

Group type: EXPERIMENTAL
Intervention: IFN alone 3 MU three times a week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: IFN 3 MU three times a week + UDCA 250 mg twice a day
Number of subjects: 108

Group type: COMPARATOR
Intervention: UDCA alone 250 mg twice a day
Number of subjects: 108
Study: 8471127

Group type: EXPERIMENTAL
Intervention: Bright visor (6000 lux) for 30 or 60 minutes in the morning for 1 week
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dim visor (400 lux) for 30 or 60 minutes in the morning for 1 week
Number of subjects: 55
Study: 3326393

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral PGE2 given hourly for two 12-h periods
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Combination of PGE2 priming and induction of labor with oxytocin
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 29898851

Group type: EXPERIMENTAL
Intervention: Video information (three-dimensional educational video)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Standard information
Number of subjects: 821
Study: 27631254

Group type: EXPERIMENTAL
Intervention: Cap-assisted colonoscopy (CAP group)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard colonoscopy (non-CAP group)
Number of subjects: 183
Study: 24638843

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 3746

Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 3746
Study: 22317756

Group type: EXPERIMENTAL
Intervention: Vitamin D (25 μg/d as cholecalciferol)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20075050

Group type: EXPERIMENTAL
Intervention: Pre- and post-bronchodilator spirometry or a single bronchial challenge test
Number of subjects: 540

Group type: COMPARATOR
Intervention: Tapering of asthma medications and repeated bronchial challenge tests
Number of subjects: 540
Study: 18591761

Group type: EXPERIMENTAL
Intervention: Therapeutic Kinesio Tape (KT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham Kinesio Tape
Number of subjects: 42
Study: 15573239

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Open hemorrhoidectomy using Ligasure
Number of subjects: 95
Study: 11333516

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Haloperidol (HAL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Risperidone (RIS)
Number of subjects: 100
Study: 9613362

Group type: EXPERIMENTAL
Intervention: Stadiometer (H)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gulliver (G)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Book and tape method (TM)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gulliver (G) and Book/Tape Method (TM)
Number of subjects: 32